| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 144 |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
– PACE-1 trial of ALTO-207 in treatment-resistant depression (TRD) on track; topline data in 2H 2027 – |
| 30 Oct 2026 | SCHEDULE 13G |
| 05 Oct 2026 |
Form 4: Smith Nicholas Conrad, PRESIDENT AND CFO
Received 55,000 shares by exercise or conversion ($128K) |
| 01 Oct 2026 |
Form 4: Smith Nicholas Conrad, PRESIDENT AND CFO
Received 110,830 shares by exercise or conversion ($260K) · Sold 110,830 shares ($2.95M) · Received 24,056 shares by exercise or conversion ($56.5K) · 1 more |
| 29 Sep 2026 | 144 |
| 27 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
As you know, you are currently employed at Alto Neuroscience, Inc. (the “Company”) as Chief Financial Officer and Chief Business Officer pursuant to the terms of an offer letter dated November 20, 2023, as amended by a letter agreement d... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
– ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial; topline Phase 2b dat... |
| 27 Jul 2026 | SCHEDULE 13G |
| 20 Jul 2026 | SCHEDULE 13G |
| 14 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
Alto Neuroscience, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall... |
| 14 Jul 2026 | 424B5 |
| 13 Jul 2026 |
8-K: Results of Operations and Financial Condition; Other Events
The information disclosed under the heading “Cash, Cash Equivalents and Restricted Cash as of June 30, 2026” under Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference and shall not be deemed “filed” for purpo... |
| 29 May 2026 |
Form 4: Miller Andrew Craig, Director
Granted 26,000 Stock Option (right to buy) |
| 29 May 2026 |
Form 3: Miller Andrew Craig, Director
No securities owned |
Loading...